Robert Cincotta: Fetal Vulnerability in Anti-Ro/SSA and Anti-La/SSB Antibody-Positive Pregnancies
Robert Cincotta, Director and Founder at QUFW, shared a post on LinkedIn about a paper by Zeinab F. Saleh et al. published in AJOG:
“For years, one question has stayed with me.
Why do anti-Ro/SSA and anti-La/SSB antibodies which maybe present for decades in women with Lupus or Sjögren’s syndrome, leave the mother’s heart untouched, yet during a narrow window of fetal development can permanently damage a baby’s cardiac conduction system?
We know the outcome too well: irreversible complete heart block, pacing in infancy, lifelong consequences and sometimes, loss.
The devastation is real, yet strikingly selective.
Around 2% of antibody-positive pregnancies are affected. If a woman has had one affected child, the recurrence risk in a subsequent pregnancy rises to nearly 20%.
The explanation lies in fetal vulnerability.
During mid-gestation, the fetal conduction system is still forming. Maternal autoantibodies cross the placenta, trigger inflammation, and ultimately fibrosis of the AV node. The mature maternal heart with stable calcium channel expression and structural redundancy, simply isn’t susceptible in the same way.
That biology matters. Because it gives us a therapeutic foothold.
A recent AJOG expert review looks at clinical outcomes and safety evidence for hydroxychloroquine (HCQ) in pregnancy. Beyond its established role in lupus, HCQ is safe in pregnancy and significantly reduces recurrence of congenital heart block in anti-SSA/SSB positive pregnancies.
For me, the take home message isn’t just about a medication.
It’s about understanding why the fetus is uniquely vulnerable and how aligning therapy with developmental biology can change outcomes.”
Title: Hydroxychloroquine in systemic lupus erythematosus, anti-SSA/SSB, and antiphospholipid antibody-positive pregnancies
Authors: Zeinab F. Saleh, Emily C. Somers, Vivian C. Romero, Wendy Marder
Read the full article.
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Feb 5, 2026, 16:22Plamen Todorov: Microfluidics for IVF: From Science to Clinical Validation
-
Feb 5, 2026, 16:18Impact of Bushfire Exposure on ART Outcomes Explored – RBMO
-
Feb 5, 2026, 16:13Transforming Contraception and Oncofertility with AMH Insights – SSR
-
Feb 4, 2026, 00:43Join the 2026 Rising Stars Webinar On February 11 – SSR
-
Feb 4, 2026, 00:18Dalia Alqarni: Urinary Incontinence’s Impact on Women’s Health
-
Feb 4, 2026, 00:16New Study Reveals IVF Success for Women With Endometriosis – Fertility Plus
-
Feb 4, 2026, 00:13Tamuka Chekero: Exploring Relational Autonomy in Infertility Across Cultures
-
Feb 2, 2026, 13:04Optimal GnRH Agonist Dosage for Oocyte Maturation – Fertility and Sterility
-
Feb 2, 2026, 12:39Family Planning Challenges for Women with Lupus – The Lupus Foundation of Australasia